In this discussion, Apoorva Gangavelli, MD (Emory School of Medicine, CardioNerds Academy House Chief), and Daniel Judge, MD (Medical University of South Carolina), break down data presented at ESC Heart Failure 2026 from the ATTRibute-CM trial. The conversation focuses on outpatient worsening heart failure in transthyretin amyloid cardiomyopathy (ATTR-CM), emphasizing the clinical relevance of sustained loop diuretic initiation or escalation as an early signal of disease progression. As hospitalization thresholds rise and more care shifts to the outpatient setting, Dr. Judge highlights how recognizing these subtle changes may better capture patient trajectory and treatment effects in both clinical practice and trials.
This transcript has been edited for clarity.
Apoorva Gangavelli, MD: Welcome back, Cardio Nerds. I’m Apoorva Gangavelli, one of the chiefs of the CardioNerds Academy and the incoming cardiology fellow at Emory. We’re here covering key science from ESC Heart Failure 2026. We’ll be discussing outpatient worsening heart failure in transthyretin amyloid cardiomyopathy from the ATRIBUTE-CM trial.
I’m delighted today to be joined by Dr. Dan Judge, professor of medicine at MUSC and one of the leaders in amyloid. Dr. Judge, thank you for joining us.